Although metastatic melanoma still carries substantial mortality rates, targeted therapy involving BRAF/MEK inhibition and immunotherapy utilizing PD-1/PD-L1 inhibitors along with CTLA-4 inhibitors has led to remarkable advancements in treatment outcomes and prognosis improvement [11,12,13,14]. This evidence concerns the gene MAP2K7 and metastatic melanoma.